Clinical trial
A Phase 1, Double-blind, Placebo-controlled, Multiple Intravenous, Ascending-Dose Study of CNTO 136 to Evaluate Safety and Pharmacokinetics in Subjects With Cutaneous Lupus Erythematosus and to Evaluate Safety and Pharmacokinetics in a Cohort of Subjects With Systemic Lupus Erythematosus
NCT01702740 is registered in ClinicalTrials.gov with Centocor Research & Development, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Double-blind, Placebo-controlled, Multiple Intravenous, Ascending-Dose Study of CNTO 136 to Evaluate Safety and Pharmacokinetics in Subjects With Cutaneous Lupus Erythematosus and to Evaluate Safety and Pharmacokinetics in a Cohort of Subjects With Systemic Lupus Erythematosus
- Lead sponsor
- Centocor Research & Development, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 31, 2007
- Completion date
- October 31, 2009
- Enrollment
- 49 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.